<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04369469</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-COV-305</org_study_id>
    <nct_id>NCT04369469</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia</brief_title>
  <official_title>A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared With Best Supportive Care in Patients With COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of
      ravulizumab administered in adult patients with Coronavirus Disease 2019 (COVID-19) severe
      pneumonia, acute lung injury, or acute respiratory distress syndrome. Patients will be
      randomly assigned to receive ravulizumab in addition to best supportive care (BSC) (2/3 of
      the patients) or BSC alone (1/3 of the patients). Best supportive care will consist of
      medical treatment and/or medical interventions per routine hospital practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 11, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival (based on all-cause mortality) at Day 29</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of days free of mechanical ventilation at Day 29</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in SpO2/FiO2 at Day 29</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of intensive care unit stay at Day 29</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Sequential Organ Failure Assessment at Day 29</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival (based on all-cause mortality) at Day 60 and Day 90</measure>
    <time_frame>Baseline, Day 60, Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome</condition>
  <condition>Pneumonia, Viral</condition>
  <arm_group>
    <arm_group_label>Ravulizumab plus Best Supportive Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>Weight-based doses of ravulizumab will be administered intravenously on Days 1, 5, 10, and 15.</description>
    <arm_group_label>Ravulizumab plus Best Supportive Care</arm_group_label>
    <other_name>Ultomiris</other_name>
    <other_name>ALXN1210</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>Patients will receive medications, therapies, and interventions per standard hospital treatment protocols.</description>
    <arm_group_label>Best Supportive Care</arm_group_label>
    <arm_group_label>Ravulizumab plus Best Supportive Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males or females ≥ 18 years of age and ≥ 40 kg at the time of providing informed
             consent

          2. Confirmed diagnosis of SARS-CoV-2 infection presenting as severe COVID-19 requiring
             hospitalization

          3. Severe pneumonia, acute lung injury, or acute respiratory distress syndrome confirmed
             by computed tomography (CT) or X-ray at Screening or within the 3 days prior to
             Screening, as part of the patient's routine clinical care

          4. Severe pneumonia, acute lung injury, or acute respiratory distress syndrome requiring
             oxygen supplementation with invasive or noninvasive mechanical ventilation

          5. Female patients of childbearing potential and male patients with female partners of
             childbearing potential must follow protocol specified contraception guidance for
             avoiding pregnancy for 8 months after treatment with the study drug

        Exclusion Criteria:

          1. Patient is not expected to survive for more than 24 hours

          2. Patient is on invasive mechanical ventilation with intubation for more than 48 hours
             prior to Screening

          3. Severe pre-existing cardiac disease (ie, New York Heart Association Class 3 or Class
             4, acute coronary syndrome or persistent ventricular tachyarrhythmias)

          4. Patient has an unresolved Neisseria meningitidis infection

          5. Use of the following medications and therapies:

               -  Current treatment with a complement inhibitor,

               -  Rituximab within 3 months of Screening,

               -  Mitoxantrone within 3 months of Screening, and

               -  Intravenous immunoglobulin (IVIg) within 3 weeks prior to Screening.

          6. Participation in another interventional treatment study within 30 days before
             initiation of ravulizumab on Day 1 in this study or within 5 half-lives of that
             investigational product, whichever is greater.

          7. Female patients who are breastfeeding or who have a positive pregnancy test result at
             Screening or on Day 1.

          8. History of hypersensitivity to any ingredient contained in the study drug, including
             hypersensitivity to murine proteins
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>+1 855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Créteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Le Kremlin-Bicêtre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS9 7TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>WHO. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected. Interim guidance, 28 January 2020.</citation>
  </reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 28, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2020</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lung injury</keyword>
  <keyword>acute respiratory distress syndrome</keyword>
  <keyword>antibodies, monoclonal, humanized</keyword>
  <keyword>COVID-19</keyword>
  <keyword>hospitalization</keyword>
  <keyword>pneumonia</keyword>
  <keyword>severe pneumonia</keyword>
  <keyword>severe acute respiratory syndrome</keyword>
  <keyword>severe acute respiratory syndrome coronavirus 2</keyword>
  <keyword>randomized controlled study</keyword>
  <keyword>ravulizumab</keyword>
  <keyword>respiratory distress syndrome, adult</keyword>
  <keyword>Ultomiris</keyword>
  <keyword>viral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia, Viral</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

